Recombinant ITGA4 (Natalizumab Biosimilar) anticorps
Aperçu rapide pour Recombinant ITGA4 (Natalizumab Biosimilar) anticorps (ABIN7795116)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody
-
Attributs du produit
- Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab. Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- Human Integrin alpha 4
-
-
anti-ITGA4 (Natalizumab Biosimilar) antibody
Research Grade Reactivité: Humain FACS Hôte: Humanized Monoclonal unconjugated Recombinant Antibody
anti-ITGA4 (Natalizumab Biosimilar) antibodyReactivité: Humain FACS, BR Hôte: Lapin Chimeric unconjugated Recombinant Antibody
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ITGA4 (Natalizumab Biosimilar)
-
Autre désignation
- Natalizumab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-
